| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03ff8e060efb78450d8501f671e2de1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_587d32d5e58cdcbf9cef902174eaa73d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c394b038e6ea703aea043d3e22ac5c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ea5203c7c94a36da317f4e3ec368490 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate |
2007-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0457a5f4323c626bcb7fa0aef0369e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_683186304d2e5f588908a96978aef247
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48fd9f889c01d6ae5049743209790565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52ac67dd8dd4246f2ecde024d1bdbd37 |
| publicationDate |
2009-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20090033328-A |
| titleOfInvention |
Immune Privileges and Regulating Progenitor Cells |
| abstract |
Described herein is a method of modulating an immune response between a lymphocyte and an object recognized by the lymphocyte as foreign. The method utilizes the immunomodulatory activity of a new class of progenitor cells called HUCPVCs, derived from the perivascular region of the human umbilical cord. The method also uses soluble factors exuded from cultured HUCPVCs. The method is useful for treating immune diseases including graft versus host disease, autoimmune diseases and the like. |
| priorityDate |
2006-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |